{"transactions":[{"id":980574,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":83230,"price":0.97,"value":80733.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology."}],"balance_after":4784111,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980573,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":57225,"price":0.87,"value":49785.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology."}],"balance_after":4867341,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980572,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":59277,"price":0.89,"value":52756.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,070 by MPM Asset Management LLC (\"AM LLC\"), 25,712 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,715 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 884 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,662 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,234 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology."}],"balance_after":4924566,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":985366,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":60917,"price":0.94,"value":57261.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology."}],"balance_after":4983843,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985365,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":20277,"price":0.99,"value":20074.23,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology."}],"balance_after":5044760,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985364,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":60733,"price":0.98,"value":59518.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,170 by MPM Asset Management LLC (\"AM LLC\"), 26,343 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,757 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 907 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,801 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,755 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology."}],"balance_after":5065037,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":989048,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":42533,"price":0.92,"value":39130.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology."}],"balance_after":5125770,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":989047,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":88802,"price":0.98,"value":87025.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology."}],"balance_after":5168303,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":989046,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":64331,"price":0.83,"value":53394.73,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,417 by MPM Asset Management LLC (\"AM LLC\"), 27,904 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,861 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 960 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 6,145 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 23,044 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology."}],"balance_after":5257105,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":992831,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-20","kind":"sale","planned":true,"acquired":false,"shares":41152,"price":0.89,"value":36625.28,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of\nthe Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology."}],"balance_after":5321436,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":992830,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":66324,"price":0.94,"value":62344.56,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology."}],"balance_after":5362588,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":992829,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":52627,"price":0.93,"value":48943.11,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,613 by MPM Asset Management LLC (\"AM LLC\"), 22,827 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,523 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 786 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,027 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 18,851 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology."}],"balance_after":5428912,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":998125,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":57061,"price":0.95,"value":54207.95,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology."}],"balance_after":5481539,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":998124,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":61640,"price":0.93,"value":57325.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology."}],"balance_after":5538600,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":998123,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":90951,"price":0.98,"value":89131.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 6,244 by MPM Asset Management LLC (\"AM LLC\"), 39,450 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,631 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,359 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 8,688 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 32,579 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology."}],"balance_after":5600240,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":1002534,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-12","kind":"sale","planned":true,"acquired":false,"shares":40669,"price":1.09,"value":44329.21,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology."}],"balance_after":5691191,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002533,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":55810,"price":1.14,"value":63623.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology."}],"balance_after":5731860,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002532,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":48570,"price":1.18,"value":57312.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology."}],"balance_after":5787670,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002531,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-07","kind":"sale","planned":true,"acquired":false,"shares":68480,"price":1.11,"value":76012.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,702 by MPM Asset Management LLC (\"AM LLC\"), 29,704 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,981 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,022 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 6,541 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 24,530 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology."}],"balance_after":5836240,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1006039,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-06","kind":"sale","planned":true,"acquired":false,"shares":54452,"price":1.21,"value":65886.92,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology."}],"balance_after":5904720,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1006038,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":47950,"price":1.22,"value":58499.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology."}],"balance_after":5959172,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1006037,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":140488,"price":1.22,"value":171395.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 9,645 by MPM Asset Management LLC (\"AM LLC\"), 60,937 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,420 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 50,324 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology."}],"balance_after":6007122,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1009818,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":94063,"price":1.29,"value":121341.27,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology."}],"balance_after":6147610,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1009817,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-10-31","kind":"sale","planned":true,"acquired":false,"shares":114044,"price":1.28,"value":145976.32,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology."}],"balance_after":6241673,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1009816,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-10-30","kind":"sale","planned":true,"acquired":false,"shares":86936,"price":1.43,"value":124318.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,969 by MPM Asset Management LLC (\"AM LLC\"), 37,709 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 8,304 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 31,141 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology."}],"balance_after":6355717,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1012193,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":134240,"price":1.55,"value":208072.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology"},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology."}],"balance_after":6442653,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1012192,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":69068,"price":1.64,"value":113271.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology."}],"balance_after":6576893,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1012191,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-27","kind":"sale","planned":true,"acquired":false,"shares":72709,"price":1.72,"value":125059.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,992 by MPM Asset Management LLC (\"AM LLC\"), 31,538 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,945 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 26,045 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology."}],"balance_after":6645961,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1147830,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":2,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":3,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":4,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-05-15T21:34:15.000Z","date":"2025-05-13","kind":"sale","planned":false,"acquired":false,"shares":1031931,"price":8.06,"value":8317363.86,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. (\"BV 2014\"),  22,386 by MPM BioVentures 2014 (B), L.P. (\"BV 2014(B)\"), 12,233 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 224,467 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 11,267 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 4,432 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 401,740 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F2","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3452797,"source":{"system":"sec-edgar","filing":"0001415889-25-013252","document":"form4-05152025_090510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925013252/form4-05152025_090510.xml","form_type":"4"}},{"id":1163512,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":false,"shares":42842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology."}],"balance_after":0,"derivative":{"exercise_price":0.09,"expiration_date":"2025-08-13","underlying":"Common Stock","underlying_shares":42842},"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163511,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":false,"shares":8031,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The warrants were held as follows:  3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology."}],"balance_after":0,"derivative":{"exercise_price":0.09,"expiration_date":"2025-04-09","underlying":"Common Stock","underlying_shares":8031},"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163510,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"sale","planned":false,"acquired":false,"shares":4386,"price":1.05,"value":4605.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6718670,"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163509,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":true,"shares":50873,"price":0.09,"value":4578.57,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 461,408 by MPM Asset Management LLC (\"AM LLC\"), 2,915,905 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 194,486 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 100,365 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 640,121 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 2,410,771 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology.  Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6723056,"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1867237,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T16:37:26.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":false,"shares":3370982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities were held in the account of UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-034346","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919123034346/doc4.xml","form_type":"4"}},{"id":2441902,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":30347,"price":42.03,"value":1275484.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 10,804 by BV 2014, 372 by AM BV2014, 6,824 by BV 2018, 135 by AM BV2018 and 12,212 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 1,544,580 by BV 2014, 97,289 by, 53,164 by AM BV2014, 975,523 by BV 2018, 48,966 by BV 2018(B), 19,263 by AM BV2018 and 1,745,943 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4484728,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441901,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":12829,"price":46.47,"value":596163.63,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 4,590 by BV 2014, 154 by AM BV2014, 2,874 by  BV 2018, 53 by AM BV2018 and 5,158 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $46.965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,555,384 by BV 2014, 97,289 by BV 2014(B), 53,536 by AM BV2014, 982,347 by BV 2018, 48,966 by BV 2018(B), 19,398 by AM BV2018 and 1,758,155 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4515075,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441900,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":11318,"price":45.32,"value":512931.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 4,050 by BV 2014, 133 by AM BV2014, 2,544 by  BV 2018, 41 by AM BV2018 and 4,550 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,559,974 by BV 2014, 97,289 by BV 2014(B), 53,690 by AM BV2014, 985,221 by BV 2018, 48,966 by BV 2018(B), 19,451 by AM BV2018 and 1,763,313 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4527904,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441899,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":32396,"price":43.2,"value":1399507.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 11,534  by BV 2014, 390 by AM BV2014, 7,300 by BV 2018, 142 by AM BV2018 and 13,030 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,564,024 by BV 2014, 97,289 by BV 2014(B), 53,823 by AM BV2014, 987,765 by BV 2018, 48,966 by BV 2018(B), 19,492 by AM BV2018 and 1,767,863 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4539222,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441898,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":158579,"price":42.05,"value":6668246.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 56,414 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,959 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 35,653 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 719 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 63,834 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,575,558 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 54,213 by AM BV2014, 995,065 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 19,634 by AM BV2018 and 1,780,893 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4571618,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2482712,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":2499,"price":34.11,"value":85240.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F25","text":"The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018, 11 by AM BV2018 and 1,005 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F26","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F27","text":"The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172  by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B), 20,353 by AM BV2018 and 1,844,727 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4730197,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482711,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":30059,"price":33.15,"value":996455.85,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F22","text":"The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018, 134 by AM BV2018 and 12,097 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F24","text":"The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B), 20,364 by AM BV2018 and 1,845,732 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4732696,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482710,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":100,"price":35.04,"value":3504.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F20","text":"The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018, 1 by AM BV2018 and 40 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F21","text":"The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B), 20,498 by AM BV2018 and 1,857,829 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4762755,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482709,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":850,"price":34.08,"value":28968.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F17","text":"The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018, 4 by AM BV2018 and 342 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B), 20,499 by AM BV2018 and 1,857,869 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4762855,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482708,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":1960,"price":33.57,"value":65797.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018, 8 by AM BV2018 and 789 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 1,643,901 by BV 2014, 97,289 by, 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B), 20,503 by AM BV2018 and 1,858,211 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4763705,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482707,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":14173,"price":32.35,"value":458496.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by  BV 2018, 63 by AM BV2018 and 5,704 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B), 20,511 by AM BV2018 and 1,859,000 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4765665,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482706,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":300,"price":36.26,"value":10878.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by  BV 2018, 1 by AM BV2018 and 121 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B), 20,574 by AM BV2018 and 1,864,704 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4779838,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482705,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":4047,"price":35.44,"value":143425.68,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018, 18 by AM BV2018 and 1,628 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B), 20,575 by AM BV2018 and 1,864,825 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4780138,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482704,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":29402,"price":34.68,"value":1019661.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"shares","element":"transactionShares","label":"F3","text":"The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 359  by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,612 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 131 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 11,833 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,651,193 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 20,593 by AM BV2018 and 1,866,453 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4784185,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2489265,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":12434,"price":34.83,"value":433076.22,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F21","text":"The shares were sold as follows: 4,427 by BV 2014, 152 by AM BV2014, 2,796 by BV 2018, 55 by AM BV2018 and 5,004 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F23","text":"The shares are held as follows: 1,661,660 by BV 2014, 97,289 by BV 2014(B), 57,193 by AM BV2014, 1,049,469 by BV 2018, 48,966 by BV 2018(B), 20,724 by AM BV2018 and 1,878,286 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4813587,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489264,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":49796,"price":33.74,"value":1680117.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F18","text":"The shares were sold as follows: 17,728 by BV 2014, 611 by AM BV2014, 11,197 by BV 2018, 221 by AM BV2018 and 20,039 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"The shares are held as follows: 1,666,087 by BV 2014, 97,289 by BV 2014(B), 57,345 by AM BV2014, 1,052,265 by BV 2018, 48,966 by BV 2018(B), 20,779 by AM BV2018 and 1,883,290 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4826021,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489263,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1500,"price":35.34,"value":53010.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 534 by BV 2014, 18 by AM BV2014, 337 by BV 2018, 7 by AM BV2018 and 604  by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 1,683,815 by BV 2014, 97,289 by, 57,956 by AM BV2014, 1,063,462 by BV 2018, 48,966 by BV 2018(B), 21,000 by AM BV2018 and 1,903,329 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4875817,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489262,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":9131,"price":34.61,"value":316023.91,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 3,251 by BV 2014, 112 by AM BV2014, 2,053 by  BV 2018, 41 by AM BV2018 and 3,674 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,684,349 by BV 2014, 97,289 by BV 2014(B), 57,974 by AM BV2014, 1,063,799 by BV 2018, 48,966 by BV 2018(B), 21,007 by AM BV2018 and 1,903,933 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4877317,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489261,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":10111,"price":33.82,"value":341954.02,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,600 by BV 2014, 124 by AM BV2014, 2,274 by  BV 2018, 44  by AM BV2018 and 4,069 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,687,600 by BV 2014, 97,289 by BV 2014(B), 58,086 by AM BV2014, 1,065,852 by BV 2018, 48,966 by BV 2018(B), 21,048 by AM BV2018 and 1,907,607 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4886448,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489260,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":46992,"price":35.19,"value":1653648.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 16,733 by BV 2014, 576 by AM BV2014, 10,569 by BV 2018, 198 by AM BV2018 and 18,916 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.93 to $35.465 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,691,200 by BV 2014, 97,289 by BV 2014(B), 58,210 by AM BV2014, 1,068,126 by BV 2018, 48,966 by BV 2018(B), 21,092 by AM BV2018 and 1,911,676 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4896559,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489259,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":9809,"price":34.62,"value":339587.58,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,494 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 120 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,206 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 41 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 3,948 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.93 to $34.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,707,933 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 58,786 by AM BV2014, 1,078,695 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 21,290 by AM BV2018 and 1,930,592 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4943551,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2492304,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":500,"price":35.37,"value":17685.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 178 by BV 2014, 6 by AM BV2014, 112 by  BV 2018, 2 by AM BV2018 and 202 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.125 to $35.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B), 21,331 by AM BV2018 and 1,934,540 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4953360,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2492303,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":16856,"price":34.46,"value":580857.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by  BV 2018, 75 by AM BV2018 and 6,783 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.86  inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B), 21,333 by AM BV2018 and 1,934,742 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4953860,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2492302,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":10258,"price":36.03,"value":369595.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018, 45 by AM BV2018 and 4,129 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B), 21,408 by AM BV2018 and 1,941,525 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4970716,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2492301,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":10952,"price":35.49,"value":388686.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,899 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 134 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,463 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 49 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 4,407 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.915 to $35.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,721,258 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 59,245  by AM BV2014, 1,087,109 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 21,453 by AM BV2018 and 1,945,654 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4980974,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2496205,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":21965,"price":37.02,"value":813144.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F24","text":"The shares were sold as follows: 7,820 by BV 2014, 269 by AM BV2014, 4,939 by BV 2018, 98 by AM BV2018 and 8,839 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F25","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.85 to $37.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F26","text":"The shares are held as follows: 1,725,157 by BV 2014, 97,289 by BV 2014(B), 59,379 by AM BV2014, 1,089,572 by BV 2018, 48,966 by BV 2018(B), 21,502 by AM BV2018 and 1,950,061 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4991926,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496204,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":30696,"price":36.05,"value":1106590.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F21","text":"The shares were sold as follows: 10,929 by BV 2014, 376 by AM BV2014, 6,902 by BV 2018, 136 by AM BV2018 and 12,353 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.83 to $36.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F23","text":"The shares are held as follows: 1,732,977 by BV 2014, 97,289 by BV 2014(B), 59,648 by AM BV2014, 1,094,511 by BV 2018, 48,966 by BV 2018(B), 21,600 by AM BV2018 and 1,958,900 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5013891,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496203,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":8147,"price":35.2,"value":286774.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F18","text":"The shares were sold as follows: 2,900 by BV 2014, 100 by AM BV2014, 1,832 by BV 2018, 36 by AM BV2018 and 3,279 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.82 to $35.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"The shares are held as follows: 1,743,906 by BV 2014, 97,289 by BV 2014(B), 60,024 by AM BV2014, 1,101,413 by BV 2018, 48,966 by BV 2018(B), 21,736 by AM BV2018 and 1,971,253 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5044587,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496202,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":600,"price":36.5,"value":21900.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 214 by BV 2014, 7 by AM BV2014, 135 by  BV 2018, 3 by AM BV2018 and 241 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 1,746,806  by BV 2014, 97,289 by BV 2014(B), 60,124 by AM BV2014, 1,103,245 by BV 2018, 48,966 by BV 2018(B), 21,772 by AM BV2018 and 1,974,532 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5052734,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496201,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":32876,"price":36.21,"value":1190439.96,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 11,704 by BV 2014, 403 by AM BV2014, 7,392 by  BV 2018, 146 by AM BV2018 and 13,231  by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,747,020 by BV 2014, 97,289 by BV 2014(B), 60,131 by AM BV2014, 1,103,380 by BV 2018, 48,966 by BV 2018(B), 21,775 by AM BV2018 and 1,974,773 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5053334,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496200,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":19758,"price":37.81,"value":747049.98,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 7,034 by BV 2014, 242 by AM BV2014, 4,443 by BV 2018, 88 by AM BV2018 and 7,951 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.58 to $38.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,758,724 by BV 2014, 97,289 by BV 2014(B), 60,534 by AM BV2014, 1,110,772 by BV 2018, 48,966 by BV 2018(B), 21,921 by AM BV2018 and 1,988,004 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5086210,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496199,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":15575,"price":37.16,"value":578767.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 5,545 by BV 2014, 191 by AM BV2014, 3,502 by BV 2018, 69 by AM BV2018 and 6,268 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.58 to $37.555 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,765,758 by BV 2014, 97,289 by, 60,776 by AM BV2014, 1,115,215 by BV 2018, 48,966 by BV 2018(B), 22,009 by AM BV2018 and 1,995,955 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5105986,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496198,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-17","kind":"other","acquired":false,"shares":15671,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata in-kind distribution from MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\") and MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\") to its respectve limited partners for no consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were distributed as follows: 10,424 by BV 2014(B) and 5,247 by BV 2018(B)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,771,303 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 97,289 by BV2014(B), 60,967 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 1,118,717 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 48,966 by BV 2018(B), 22,078 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 2,002,223 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5121543,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2540785,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-18T20:33:41.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":10320,"price":27.14,"value":280084.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,676 by BV 2014, 125 by AM BV2014, 2,321 by  BV 2018, 45 by AM BV2018 and 4,153 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,771,303 by BV 2014, 107,713 by BV 2014(B), 60,967 by AM BV2014, 1,118,717 by BV 2018, 54,213 by BV 2018(B), 22,078 by AM BV2018 and 2,002,223 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5137214,"source":{"system":"sec-edgar","filing":"0001209191-21-060722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060722/doc4.xml","form_type":"4"}},{"id":2540784,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-18T20:33:41.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":3413,"price":28.01,"value":95598.13,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,215 by BV 2014, 42 by AM BV2014, 767 by BV 2018, 15 by AM BV2018 and 1,374 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,774,979 by BV 2014, 107,713 by BV 2014(B), 61,092 by AM BV2014, 1,121,038 by BV 2018, 54,213 by BV 2018(B), 22,123 by AM BV2018 and 2,006,376 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5147534,"source":{"system":"sec-edgar","filing":"0001209191-21-060722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060722/doc4.xml","form_type":"4"}},{"id":2540783,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-18T20:33:41.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":14882,"price":27.53,"value":409701.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,298 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 182 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 3,347 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 66 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 5,989 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,776,194 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 61,134 by AM BV2014, 1,121,805 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 22,138 by AM BV2018 and 2,007,750 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5150947,"source":{"system":"sec-edgar","filing":"0001209191-21-060722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060722/doc4.xml","form_type":"4"}},{"id":2542624,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T21:26:35.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":45719,"price":27.3,"value":1248128.7,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 16,277 by BV 2014, 560 by AM BV2014, 10,280 by  BV 2018, 203 by AM BV2018 and 18,399 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,781,492 by BV 2014, 107,713 by BV 2014(B), 61,316 by AM BV2014, 1,125,152 by BV 2018, 54,213 by BV 2018(B), 22,204 by AM BV2018 and 2,013,739 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5165829,"source":{"system":"sec-edgar","filing":"0001209191-21-060489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060489/doc4.xml","form_type":"4"}},{"id":2542623,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T21:26:35.000Z","date":"2021-10-13","kind":"sale","acquired":false,"shares":35023,"price":27.13,"value":950173.99,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 12,469 by BV 2014, 429 by AM BV2014, 7,875 by BV 2018, 156  by AM BV2018 and 14,094 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,797,769 by BV 2014, 107,713 by BV 2014(B), 61,876 by AM BV2014, 1,135,432 by BV 2018, 54,213 by BV 2018(B), 22,407 by AM BV2018 and 2,032,138 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5211548,"source":{"system":"sec-edgar","filing":"0001209191-21-060489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060489/doc4.xml","form_type":"4"}},{"id":2542622,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T21:26:35.000Z","date":"2021-10-12","kind":"sale","acquired":false,"shares":14260,"price":27.09,"value":386303.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,077 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 175 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 3,206 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 63 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 5,739 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,810,238 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 62,305 by AM BV2014, 1,143,307 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 22,563 by AM BV2018 and 2,046,232 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5246571,"source":{"system":"sec-edgar","filing":"0001209191-21-060489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060489/doc4.xml","form_type":"4"}},{"id":2544708,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T20:33:23.000Z","date":"2021-10-11","kind":"sale","acquired":false,"shares":81684,"price":27.24,"value":2225072.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 29,081 by BV 2014, 1,001 by AM BV2014, 18,367 by  BV 2018, 363 by AM BV2018 and 32,872 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,815,315 by BV 2014, 107,713 by BV 2014(B), 62,480 by AM BV2014, 1,146,513 by BV 2018, 54,213 by BV 2018(B), 22,626 by AM BV2018 and 2,051,971 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5260831,"source":{"system":"sec-edgar","filing":"0001209191-21-060235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060235/doc4.xml","form_type":"4"}},{"id":2544707,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T20:33:23.000Z","date":"2021-10-08","kind":"sale","acquired":false,"shares":3400,"price":27.01,"value":91834.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,210 by BV 2014, 42 by AM BV2014, 765 by BV 2018, 15 by AM BV2018 and 1,368 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,844,396 by BV 2014, 107,713 by BV 2014(B), 63,481 by AM BV2014, 1,164,880 by BV 2018, 54,213 by BV 2018(B), 22,989 by AM BV2018 and 2,084,843 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5342515,"source":{"system":"sec-edgar","filing":"0001209191-21-060235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060235/doc4.xml","form_type":"4"}},{"id":2544706,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T20:33:23.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":1922,"price":27,"value":51894.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 684 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 24 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 432 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 9 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 773 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,845,606 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 63,523 by AM BV2014, 1,165,645 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 23,004 by AM BV2018 and 2,086,211 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5345915,"source":{"system":"sec-edgar","filing":"0001209191-21-060235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121060235/doc4.xml","form_type":"4"}},{"id":2549671,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T20:31:56.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":34659,"price":27.06,"value":937872.54,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 12,339 by BV 2014, 425 by AM BV2014, 7,793 by BV 2018, 154 by AM BV2018 and 13,948 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,846,290 by BV 2014, 107,713 by BV 2014(B), 63,547 by AM BV2014, 1,166,077 by BV 2018, 54,213 by BV 2018(B), 23,013 by AM BV2018 and 2,086,984 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5347837,"source":{"system":"sec-edgar","filing":"0001209191-21-059421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121059421/doc4.xml","form_type":"4"}},{"id":2549670,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T20:31:56.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":11471,"price":27,"value":309717.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,084 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 141 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,579 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 51 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 4,616 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,858,629 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 63,972 by AM BV2014, 1,173,870 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 23,167 by AM BV2018 and 2,100,932 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5382496,"source":{"system":"sec-edgar","filing":"0001209191-21-059421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121059421/doc4.xml","form_type":"4"}},{"id":2556005,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-30T21:05:01.000Z","date":"2021-09-30","kind":"sale","acquired":false,"shares":3836,"price":27,"value":103572.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,366 by BV 2014, 47 by AM BV2014, 862 by BV 2018, 17 by AM BV2018 and 1,544 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.955 to $27.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,862,713 by BV 2014, 107,713 by BV 2014(B), 64,113 by AM BV2014, 1,176,449 by BV 2018, 54,213 by BV 2018(B), 23,218 by AM BV2018 and 2,105,548 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5393967,"source":{"system":"sec-edgar","filing":"0001209191-21-058208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121058208/doc4.xml","form_type":"4"}},{"id":2556004,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-30T21:05:01.000Z","date":"2021-09-28","kind":"sale","acquired":false,"shares":32154,"price":27,"value":868158.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 11,447 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 394 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 7,230 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 143 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 12,940 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,864,079 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 64,160 by AM BV2014, 1,177,311 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 23,235 by AM BV2018 and 2,107,092 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5397803,"source":{"system":"sec-edgar","filing":"0001209191-21-058208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121058208/doc4.xml","form_type":"4"}},{"id":2559091,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:51:09.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":19455,"price":27.09,"value":527035.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 6,926 by BV 2014, 238 by AM BV2014, 4,375 by  BV 2018, 86 by AM BV2018 and 7,830 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,875,526  by BV 2014, 107,713 by BV 2014(B), 64,554 by AM BV2014, 1,184,541 by BV 2018, 54,213 by BV 2018(B), 23,378 by AM BV2018 and 2,120,032 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5429957,"source":{"system":"sec-edgar","filing":"0001209191-21-057822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121057822/doc4.xml","form_type":"4"}},{"id":2559090,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:51:09.000Z","date":"2021-09-24","kind":"sale","acquired":false,"shares":8221,"price":27.81,"value":228626.01,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,927 by BV 2014, 101 by AM BV2014, 1,849 by  BV 2018, 36 by AM BV2018 and 3,308 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $28.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,882,452 by BV 2014, 107,713 by BV 2014(B), 64,792 by AM BV2014, 1,188,916 by BV 2018, 54,213 by BV 2018(B), 23,464 by AM BV2018 and 2,127,862 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5449412,"source":{"system":"sec-edgar","filing":"0001209191-21-057822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121057822/doc4.xml","form_type":"4"}},{"id":2559089,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:51:09.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":1200,"price":28.38,"value":34056.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 427 by BV 2014, 15 by AM BV2014, 270 by BV 2018, 5 by AM BV2018 and 483 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,885,379 by BV 2014, 107,713 by BV 2014(B), 64,893 by AM BV2014, 1,190,765 by BV 2018, 54,213 by BV 2018(B), 23,500 by AM BV2018 and 2,131,170 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5457633,"source":{"system":"sec-edgar","filing":"0001209191-21-057822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121057822/doc4.xml","form_type":"4"}},{"id":2559088,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T21:51:09.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":60600,"price":27.96,"value":1694376.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 21,575 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 743 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,626 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 269 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 24,387 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $28.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,885,806 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 64,908 by AM BV2014, 1,191,035 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 23,505 by AM BV2018 and 2,131,653 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5458833,"source":{"system":"sec-edgar","filing":"0001209191-21-057822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121057822/doc4.xml","form_type":"4"}},{"id":2561176,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:18:24.000Z","date":"2021-09-22","kind":"sale","acquired":false,"shares":23921,"price":27.54,"value":658784.34,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 8,516 by BV 2014, 293 by AM BV2014, 5,379 by BV 2018, 106 by AM BV2018 and 9,627 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 to $27.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,907,381 by BV 2014, 107,713 by BV 2014(B), 65,651 by AM BV2014, 1,204,661 by BV 2018, 54,213 by BV 2018(B), 23,774 by AM BV2018 and 2,156,040 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5519433,"source":{"system":"sec-edgar","filing":"0001209191-21-057413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121057413/doc4.xml","form_type":"4"}},{"id":2561175,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:18:24.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":32858,"price":27.47,"value":902609.26,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 11,698 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 403 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 7,388 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 146 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 13,223 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,915,897 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 65,944 by AM BV2014, 1,210,040 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 23,880 by AM BV2018 and 2,165,667 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5543354,"source":{"system":"sec-edgar","filing":"0001209191-21-057413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121057413/doc4.xml","form_type":"4"}},{"id":2564279,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:30:43.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":22930,"price":27.84,"value":638371.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 8,163 by BV 2014, 281 by AM BV2014, 5,156 by BV 2018, 101 by AM BV2018 and 9,229 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.53 to $28.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,927,595 by BV 2014, 107,713 by BV 2014(B), 66,347 by AM BV2014, 1,217,428 by BV 2018, 54,213 by BV 2018(B), 24,026 by AM BV2018 and 2,178,890 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5576212,"source":{"system":"sec-edgar","filing":"0001209191-21-056948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056948/doc4.xml","form_type":"4"}},{"id":2564278,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:30:43.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":17743,"price":27.03,"value":479593.29,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,317 by BV 2014, 217 by AM BV2014, 3,990 by BV 2018, 78 by AM BV2018 and 7,141 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.535 to $27.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,935,758 by BV 2014, 107,713 by BV 2014(B), 66,628 by AM BV2014, 1,222,584 by BV 2018, 54,213 by BV 2018(B), 24,127 by AM BV2018 and 2,188,119 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5599142,"source":{"system":"sec-edgar","filing":"0001209191-21-056948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056948/doc4.xml","form_type":"4"}},{"id":2564277,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:30:43.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":76473,"price":28.82,"value":2203951.86,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 27,226 by BV 2014, 937 by AM BV2014, 17,195 by BV 2018, 340 by AM BV2018 and 30,775 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,942,075 by BV 2014, 107,713 by BV 2014(B), 66,845 by AM BV2014, 1,226,574 by BV 2018, 54,213 by BV 2018(B), 24,205 by AM BV2018 and 2,195,260 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5616885,"source":{"system":"sec-edgar","filing":"0001209191-21-056948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056948/doc4.xml","form_type":"4"}},{"id":2564276,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:30:43.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":35565,"price":28.47,"value":1012535.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 12,662 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 436 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 7,997 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 158 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 14,312 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,969,301 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 67,782 by AM BV2014, 1,243,769 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 24,545 by AM BV2018 and 2,226,035 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5693358,"source":{"system":"sec-edgar","filing":"0001209191-21-056948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056948/doc4.xml","form_type":"4"}},{"id":2564078,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:31:24.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":3124,"price":29.06,"value":90783.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7648268,"source":{"system":"sec-edgar","filing":"0001209191-21-056914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121056914/doc4.xml","form_type":"4"}},{"id":2568121,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:03.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":1659,"price":28.15,"value":46700.85,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 591 by BV 2014, 20 by AM BV2014, 373 by BV 2018, 7 by AM BV2018 and 668 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.13 to $28.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,981,963 by BV 2014, 107,713 by BV 2014(B), 68,218 by AM BV2014, 1,251,766 by BV 2018, 54,213 by BV 2018(B), 24,703 by AM BV2018 and 2,240,347 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5728923,"source":{"system":"sec-edgar","filing":"0001209191-21-056412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056412/doc4.xml","form_type":"4"}},{"id":2568120,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:03.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":38677,"price":27.79,"value":1074833.83,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 13,770 by BV 2014, 474 by AM BV2014, 8,697 by BV 2018, 172 by AM BV2018 and 15,564 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.12 to $28.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,982,554 by BV 2014, 107,713 by BV 2014(B), 68,238 by AM BV2014, 1,252,139 by BV 2018, 54,213 by BV 2018(B), 24,710 by AM BV2018 and 2,241,015 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5730582,"source":{"system":"sec-edgar","filing":"0001209191-21-056412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056412/doc4.xml","form_type":"4"}},{"id":2568119,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:03.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":6063,"price":27.99,"value":169703.37,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 2,159 by BV 2014, 74 by AM BV2014, 1,363 by BV 2018, 27 by AM BV2018 and 2,440 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.055 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,996,324 by BV 2014, 107,713 by BV 2014(B), 68,712 by AM BV2014, 1,260,836 by BV 2018, 54,213 by BV 2018(B), 24,882 by AM BV2018 and 2,256,579 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5769259,"source":{"system":"sec-edgar","filing":"0001209191-21-056412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056412/doc4.xml","form_type":"4"}},{"id":2568118,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:46:03.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":30018,"price":27.5,"value":825495.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 10,687 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 368 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6750  by MPM BioVentures 2018, L.P. (\"BV 2018\"), 133 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 12,080 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.91 to $27.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,998,483 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 68,786 by AM BV2014, 1,262,199 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 24,909 by AM BV2018 and 2,259,019 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5775322,"source":{"system":"sec-edgar","filing":"0001209191-21-056412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121056412/doc4.xml","form_type":"4"}},{"id":2567778,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:45:06.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":6425,"price":29.16,"value":187353.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7651392,"source":{"system":"sec-edgar","filing":"0001209191-21-056411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121056411/doc4.xml","form_type":"4"}},{"id":2567777,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T20:45:06.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":7106,"price":29.17,"value":207282.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7657817,"source":{"system":"sec-edgar","filing":"0001209191-21-056411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121056411/doc4.xml","form_type":"4"}},{"id":2572264,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T23:02:29.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":35785,"price":27.64,"value":989097.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 12,740 by BV 2014, 439 by AM BV2014, 8,046 by BV 2018, 159 by AM BV2018 and 14,401 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $27.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 2,009,170 by BV 2014, 107,713 by BV 2014(B), 69,154 by AM BV2014, 1,268,949 by BV 2018, 54,213 by BV 2018(B), 25,042 by AM BV2018 and 2,271,099 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5805340,"source":{"system":"sec-edgar","filing":"0001209191-21-055745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121055745/doc4.xml","form_type":"4"}},{"id":2572263,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T23:02:29.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":11330,"price":28.73,"value":325510.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,034 by BV 2014, 139 by AM BV2014, 2,547 by BV 2018, 51 by AM BV2018 and 4,559 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.46 to $28.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 2,021,910 by BV 2014, 107,713 by BV 2014(B), 69,593 by AM BV2014, 1,276,995 by BV 2018, 54,213 by BV 2018(B), 25,201 by AM BV2018 and 2,285,500 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5841125,"source":{"system":"sec-edgar","filing":"0001209191-21-055745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121055745/doc4.xml","form_type":"4"}},{"id":2572262,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-13T23:02:29.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":11313,"price":27.86,"value":315180.18,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,027 by BV 2014, 139 by AM BV2014, 2,544 by BV 2018, 50 by AM BV2018 and 4,553 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.455 to $28.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 2,025,944 by BV 2014, 107,713 by BV 2014(B), 69,732 by AM BV2014, 1,279,542 by BV 2018, 54,213 by BV 2018(B), 25,252 by AM BV2018 and 2,290,059 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5852455,"source":{"system":"sec-edgar","filing":"0001209191-21-055745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121055745/doc4.xml","form_type":"4"}}],"next_cursor":"2021-09-13T23:02:29.000000Z,2572262"}